Ribosomal protein S6 mRNA is a biomarker upregulated in MS, downregulated by interferon treatment, and affected by season

In this Australian study, the researchers tested if T-cell activation gene expression pattern (TCAGE) in whole blood was replicated in an independent sample including 40 healthy controls and 32 untreated people with MS. 862 control individuals were used to assess heritability and seasonal expression. In addition, the effect of interferon beta treatment on expression was evaluated. The researchers succeeded in replicating the MS/TCAGE association. The expression of ribosomal protein S6 (RPS6) was higher in people with MS than controls and it was lower in the winter compared to the summer which correlated with monthly UV light index. RPS6 expression was reduced by interferon beta therapy. This data links RPS6 as a potential treatment target and biomarker for quantifying clinical response to interferon beta and other MS treatments.

Authors: Parnell GP, Gatt PN
Source: Mult Scler. 2013 Oct 14. [Epub ahead of print]

Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial